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P450s are heme containing enzymes which affect oxidation of substrates via 
catalytic intermediates having transient lifetimes. These oxidative catalytic intermediates 
are formed by a sequential interplay of electrons and protons at the active site of the 
enzyme bearing molecular dioxygen. The proton transfer to the active site from bulk 
solvent is coordinated by an “acid-alcohol” pair of active site residues which are conserved 
in all P450s. Sterol 14α-demethylases (CYP51) are P450 enzymes which catalyze 
oxidative deformylation of lanosterol in the cholesterol/ergosterol biosynthetic pathway. 
Both cholesterol and ergosterol are important regulators of membrane fluidity. CYP51 
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differs from other P450s in that the acid in the acid-alcohol pair in the active site is 
replaced by a His residue. 
 This enzyme is present in tuberculosis (TB) causing pathogen Mycobacterium 
tuberculosis (Mtb). This finding was significant for primarily two reasons. The first one 
being the baffling presence of CYP51 in Mtb, as Mtb is not known to have any 
endogenous sterol biosynthetic pathways. The second being that CYP51 is a validated drug 
target in treating fungal infections. Thus given the global resurgence of multidrug resistant 
strains of Mtb and the deadly coexsistence of Mtb in immunocompromised HIV patients, 
CYP51 may be an ideal drug target for new generation of antimycobacterial drugs.  
The Mtb CYP51 enzyme was chosen to study the proton transfer pathways in the 
active site based on the outcome of explicit solvent molecular dynamics and hybrid 
quantum mechanics/molecular mechanics calculations performed in our laboratory. Based 
on these calculations of CYP51 catalysis, Glu173 was implicated to be the proton source. 
Proton transfer to the active site occurred by a coordinated shuttling via four water 
molecules, His259 and Thr260. To experimentally verify the roles of Glu173, His259 and 
Thr260 they were mutated to alanine and biophysically characterized. Ferredoxin, an 
accessory protein required to shuttle electrons from NADPH to the CYP51 active site for 
catalysis, was also cloned using ligation independent cloning.  
We were successfully able to reconstitute the electron transport chain for CYP51. 
The mutants were found to differentially bind type I and type II enzymes. Based on 
biophysical characterization, Thr260 can be implicated to have a role in modulating the 
spin state of the enzyme. 
  1 
 
 
 
 
CHAPTER 1: BACKGROUND 
 
 
1.1   Introduction 
     Cytochrome P450s (P450s) belong to the heme containing monoxygenase family of 
enzymes. These are heme b-containing enzymes in which the iron protoporphyrin IX 
macrocycle (Figure 1) is non-covalently attached to the protein and the heme iron is axially 
coordinated by a cysteine thiolate. They are some of the most versatile oxidants found in 
nature. P450s are so called because the carbonmonoxy ferrous enzymes have a 
characteristic Soret absorbance at 450 nm. These enzymes affect functionalization of 
molecules using O2 along with a diverse set of redox partners. The resulting product thus 
contains either one or both atoms of the oxygen molecule.1 P450s are found throughout the 
biological domains and their functions can be generally classified into two roles. The first 
one is in metabolism of xenobiotics to aid their removal from the body and a second 
functional role is in biosynthesis of intermediates used for development and homeostasis.2,3 
They are also responsible for degradation of more than 70% of the clinically available 
drugs and those in the drug development pipeline. 
     P450s catalyze a host of different chemical reactions.4 They are however well known 
for their ability to efficiently hydroxylate unactivated C-H bonds. The catalytic mechanism 
of P450 occurs in a cyclic fashion putatively involving eight transient intermediates, some 
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of them being very short-lived caged radical pairs.5 It also involves interaction with protein 
redox partners which shuttle electron to the P450s from reducing equivalents, provided by 
nicotinamide adenine dinucleotide (phosphate) (NAD(P)H )in most cases (Figure 3).6,7  
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Figure 1: Iron protoporphyrin IX macrocycle with cysteine thiolate as an axial ligand. 
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Figure 2: Catalytic cycle of cytochrome P450 
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1.2  Catalytic cycle of P450 
     The catalytic cycle begins with substrate binding to the water-coordinated low spin 
(S=1/2) resting state of ferric enzyme [Figure 2 1,I]. Substrate binding causes displacement 
of water as the sixth ligand of heme and formation of high-spin (S=5/2) penta coordinate 
enzyme substrate adduct [Figure 2, II].8 This causes the midpoint redox potential of the 
heme to shift to a more positive value.9 The ultimate electron donor, NAD(P)H and its 
associated redox partners have roughly similar low redox midpoint potentials. Thus the 
sharp shift in the reduction potential resulting from substrate binding causes two electrons 
to flow from NAD(P)H to the P450 via an associated reductase, the first one of which 
generates the reduced ferrous substrate adduct [Figure 2, III].9 Subsequent binding O2 
generates an oxyferrous complex [Figure 2, IV]. The second electron from NAD(P)H then 
reduces the oxyferrous complex resulting in the Fe+3-OO2- [Figure 2, V] peroxo-ferric 
intermediate. Protonation of this intermediate leads to the Fe+3-OOH [Figure 2, VI] 
hydroperoxo-ferric intermediate, also known as Compound 0 (Cmpd 0). This is the last 
intermediate in the catalytic cycle which has been characterized using spectroscopic 
techniques.10,11 A second protonation of this intermediate leads to O-O bond lysis forming 
the highly transient and reactive oxo ferryl porphyrin π radical cation complex [Figure 2, 
VII] also known as Compound I (Cmpd I). Cmpd I is one of the most powerful oxidants in 
biology, causing substrate oxidation by the commonly accepted hydrogen atom 
abstraction-hydroxyl radical rebound mechnism.12,13 The enzyme then returns to its resting 
state. 
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     In addition to the normal cycle, there are three uncoupling reactions within the cycle 
which lead to the enzyme substrate adduct [Figure 2, II].14 The first one is the auto-
oxidation of the oxyferrous enzyme [Figure 2, IV] with simultaneous generation of a 
superoxide anion. The second one is where the hydroperoxo anion dissociates from the 
hydroperoxo ferric intermediate [Figure 2, VI], liberating hydrogen peroxide and leading 
to cycle completion, however the substrate turnover is incomplete. In the oxidase shunt the 
oxoferryl intermediate [Figure 2, VII] is oxidized to water in lieu of substrate oxidation. 
     Given the important metabolic role, the varied and unusual nature of chemistry 
(oxidation of unactivated alkanes at room temperature and physiological pH) carried out by 
P450 enzymes; they have attracted attention from pharmacologists, organic, inorganic and 
physical chemists alike. The mechanistic elucidation of these enzymes, particularly O2 
activation, proton transfer pathways and isolation of intermediates remain among the most 
researched and debated areas. Most studies have used iron protoporphyrin IX macrocycle 
mimetics, substrate analogs, spectroscopic studies and molecular biology techniques. 
Comparison of P450 enzymes with other similar heme containing, oxidizing enzymes like 
peroxidases,16 catalases, heme oxygenases,17 and nitric oxide synthases18 have given 
insight into their mechanism. 
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Figure 3: P450s and their associated redox systems.15 Type I systems use a FAD 
containing ferredoxin reductase and an iron-sulfur containing ferredoxin to shuttle 
electrons to P450 from NAD(P)H. Type II systems utilize a diflavin (FAD and FMN) 
containing membrane bound NADPH cytochrome P450 reductase to shuttle electrons to 
P450s. 
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1.3   Active site structure of P450s 
     The overall structure of P450s is conserved and made up of four-helices, three of which 
are parallel D, L and I while helix E is antiparallel.15 The heme group is confined between 
the I-helix on the distal side and L helix on the proximal side and is bound to the adjacent 
Cys-ligand-loop (Figure 4 A), containing the signature P450 sequence 
‘FxxxGx(H/R)xCxG’ (black dashed box, Figure 5). The sulfur thiolate of the cysteine is 
the proximal ligand to the heme iron and is responsible for the characteristic Soret 
absorbance at 450 nm.19 It is absolutely conserved in all P450s (highlighted in red in 
Figure 5). Water forms distal ligand in the resting state of the enzyme.  
     The I helix traverses across the active site and contains the conserved sequence 
‘(A/G)Gx(E/D/H)T’ (red dashed box, Figure 5) centered at a kink over the heme. A 
primary structure alignment of P450s reveals a conserved acid-alcohol pair in the active 
site (highlighted in blue in Figure 5, Figure 4 B).20 The alcohol residue is typically 
threonine or serine and the acid residue being aspartate or glutamate. The alcohol residue is 
implicated in the key role of proton source for the peroxo species and/or stabilizing 
hydrogen bond and water molecule network for proton delivery and O-O bond scission.21 
Mutations in the acid residue result in decreased catalytic turnover of the enzyme.22 
Subsequent investigations have suggested its role in second electron transfer and further 
events leading to Cmpd I formation.23 
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A) 
 
 
 
 
 
 
 
 
B) 
 
 
 
 
 
 
 
Figure 4: The structures of a typical P450 showing A) over all fold of P450cam (PDB 
code 1AKD)24, a camphor monoxygenase from Pseudomonas putida, with helices labeled 
and B) active site structure showing the heme, the cysteine thiolate ligand and the 
conserved acid-alcohol (Asp251-Thr252) pair in the I helix. 
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Figure 5: Sequence alignment of bacterial P450s, CYP101 (green; PDB 1AKD )-P450cam 
from Pseudomonas putida,24 CYP51 (pink; PDB 1H5Z)-lanosterol 14α-demethylase from 
Mycobacterium tuberculosis,25 CYP119 (yellow; PDB 1IO9)-P450 from acidothermophilic 
archaeon Sulfolobus solfataricus,26 CYP102 (blue; PBD 1N40)- a fatty acid monoxygenase 
from Bacillus megaterium.27 Dashed boxes show the conserved sequences and highlighted 
amino acids are the conserved residues. 
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Figure 6: Structural alignment of bacterial P450s, CYP101 (green) -from Pseudomonas 
putida, CYP51 (pink)-lanosterol 14α-demethylase from Mycobacterium tuberculosis, 
CYP119 (green)-from acidothermophilic archaeon Sulfolobus solfataricus, CYP102 
(blue)- a fatty acid monoxygenase from Bacillus megaterium, showing the conserved acid-
alcohol pair and the cysteine thiolate ligand. 
 
 
 
 
Acid 
Alcohol 
Cysteine thiolate ligand 
I helix 
   
 12
1.4   Mycobacterium tuberculosis and Tuberculosis 
     Mycobacterium tuberculosis (Mtb) is a pathogenic bacterium that causes the contagious 
disease Tuberculosis (TB). It is an obligate aerobe that establishes itself in the alveolar 
macrophages of the lung in the initial stages of infection. Eventually it spreads out to other 
tissues in the body such as bones, joints and skin via blood. The disease TB is so called 
due to formation of characteristic cellular structures in the body called tubercles in which 
the Mtb bacilli thrive, protected from surroundings. Mtb is not only able to survive host 
immune responses, but also continue living and duplicate in alveolar macrophages, unlike 
most pathogenic bacteria.28 Mtb’s cellular structure and its ability to modify both, its own 
and the host’s cell membrane contribute greatly to its virulence. The cell envelope of Mtb 
is extremely complex with an additional layer rich in unusual lipids, polyketides, 
glycolipids and polysaccharides (Figure 7).29 
     TB was once thought to be virtually eradicated in developed countries due to 
development of novel antimycobacterial drugs and improved public health management. 
However with recent resurgence of multi-drug resistant (MDR) strains of Mtb and the 
immunocompromising nature of HIV virus allowing TB to thrive and spread in the host 
make the statistics associated with TB frightening (Figure 8). This has led to World Health 
Organization (WHO) recognizing TB as a potential global emergency for human health 
(WHO publication no. WHO/TB/94.177). After the discovery of the first anti-tubercular 
drug streptomycin in 1943, followed by isoniazid, para-amino salicylic acid and rifampicin 
in the early 1960s, the drug regime for TB has remained unchanged for the past 50 years.30 
The widespread emergence of MDR Mtb strains to long used antimycobacterial drugs 
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indicates the urgent need for new anti TB drugs and subsequent discovery of novel drug 
targets in Mtb. 
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Figure 7: Lipid rich cell wall of Mtb, LAM, lipoarabinomannans; LM, lipomannans; PIM, 
phosphatidylinositol mannosides.31 
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1) Estimated number of new TB cases, by country, 2007 
 
 
 
 
 
 
 
 
2) Estimated HIV prevalence in new TB cases, 2007 
 
 
 
 
 
 
 
 
 
Figure 8: Statistics associated with TB. Data from WHO TB report 2009 
(WHO/HTM/TB/2009.411) 
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1.5   P450s in Mtb 
     The complete genome sequencing of Mtb by Stewart Cole and coworkers in 1998 was 
an important step in helping to decipher Mtb’s biology.32 A surprising revelation in the 
clinically virulent strain of Mtb H37Rv was the presence of twenty different Cytochrome 
P450 genes (CYPs). While in eukaryotic systems P450 enzymes are essential for lipid 
metabolism and are clinically proven antifungal targets, for a prokaryotic organism twenty 
P450s was an unexpectedly large number. For instance in humans there are 57 P450’s in a 
genome of ~3.3 billion meaning approximately 1 P450/5.8 million bp, but in Mtb it is 1 
P450/220,000 bp of the genome (Cytochrome P450 homepage at 
http://drnelson.utmem.edu/CytochromeP450.html) However, a large number of oxidase 
enzymes complements the obligate aerobic nature of Mtb and given the lipid rich nature of 
Mtb pathogen and a potential for these P450s to serve as novel antitubercular targets, their 
structure/function characterization would open up new areas in TB therapy.33 To date, 
crystal structures of three Mtb P450s have been published (Figure 9), CYP5125, CYP12134 
and CYP13035. CYP51 is a sterol 14α-demethylase enzyme which catalyzes the 14α-
demethylastion of lanosterol (in mammals/fungi) and obtusifoliol (in plants) in the 
pathway leading to cholesterol (in mammals) and ergosterol (in plants/fungi) both being 
important regulators of membrane fluidity.36 The functions of CYP121 and CYP130 
remain unknown. Table 1 lists the putative P450 genes of which possible functions are 
known.37 Since the Mtb genome was sequenced, the presence of CYP51 has gathered 
considerable interest for two reasons, is its baffling presence in Mtb which lacks a sterol 
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biosynthetic pathway and for the fact that it is a validated clinical target in anti-fungal 
therapy.  
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Table1:  Mtb H37Rv CYPs and their possible functions 
CYP Gene Key facts/possible function 
CYP51 Rv0754c 
Sterol 14α-demethylase38,39, possible role in host sterol 
inactivation.39 
CYP121 Rv2276 Putative essential gene, possible role in virulence.40 
CYP123 Rv0766c Upregulated at high temperatures.41 
CYP125 Rv3545c Induced in macrophages, essential for infection in mice.42 
CYP128 Rv2268c Possible essential gene, required for Mtb growth in-vitro.43 
CYP130 Rv1256c Adjacent to an oxidoreductase.35 
CYP132 Rv1394c 
Possible role in Mtb virulence. Similar to fatty acid metabolizing 
P450s. 
CYP138 Rv0136 Upregulated at high temperatures.41 
CYP141 Rv3121 Surrounding genes involved in molybdenum co-factor biosynthesis 
CYP144 Rv1777 Possible role in virulence. 
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                                                                   B) 
 
 
 
 
C) 
 
 
 
 
 
 
Figure 9:  Structures of Mtb P450s A)CYP51(PDB code 1H5Z), B)CYP121(PDB code 
3G5F) and C)CYP130(PDB code 2UUQ). 
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     In my thesis here I will describe investigations in the Mycobacterium tuberculosis P450 
enzyme, sterol 14α-demethylase (CYP51) using site directed mutagenesis, UV-vis and 
resonance Raman spectroscopy, cloning and expression of a P450 accessory protein from 
Mtb Ferredoxin(Fdx) and cloning and trial expression of another P450 from Mtb, CYP132. 
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CHAPTER 2: Mutagenesis and Characterization of CYP51  
 
 
2.1   Introduction 
     The CYP51 enzymes are found throughout the biological kingdoms and are one of the 
most ancient members of the P450 family.44 CYP51 catalyzes the oxidative deformylation 
of lanosterol, concomitantly adding a double bond in three oxidative steps, each utilizing a 
single equivalent of NADPH and O2 (Figure 10).45,46 In the first step, the 14α-methyl group 
is oxidized to the corresponding alcohol. The alcohol in the next step is oxidized to a diol, 
which dehydrates to an aldehyde. The final step results in cleavage of the C14-C32 bond 
with stereoselective removal of 15α-H, resulting in the formation of a 14,15 double bond 
and release of formic acid. While the first two steps have been proposed to occur by Cmpd 
I-mediated hydrogen radical abstraction/hydroxyl radical rebound,12,13 the last step is 
thought to be mediated by the peroxo species.46 A primary sequence analysis of CYP51 
enzymes reveals that the acid in the acid-alcohol is replaced by a His residue (Figure 
5).44Conventionally, either an aspartic acid or a glutamic acid residue is found in this 
position. When the X-ray crystal structure of Mtb CYP51 is compared with those of other 
P450’s, it is revealed that this dyad occupies the same position as the conventional acid-
alcohol pair in the active site of other P450s (Figure 6). This unusual replacement raises 
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questions as to how O2 is activated in CYP51 and the subsequent modulation of the 
lifetimes of intermediates in the catalytic cycle involved in oxidative biotransformation. 
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Figure 10: Catalytic intermediates in the CYP51 catalyzed deformylation of lanosterol. 
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     A computational study by Sen and Hackett47 employed explicit solvent molecular 
dynamics (MD) simulations and hybrid quantum mechanics/molecular mechanics 
(QM/MM) techniques to provide mechanistic insight into O2 activation and characterize 
reactive oxygen intermediates in Mtb CYP51 catalysis. Simulations of the His259H+ Mtb 
CYP51 revealed evolution of two networks which could shuttle electrons to the peroxo 
species in CYP51. The first network involving His-Thr dyad could only support Cmpd 0 
formation (Figure 11, A).The second proton transfer network connected the distal O2 atom 
to His259H+ and Glu173 via four water molecules. In this configuration of the active site, 
QM/MM calculations revealed that the peroxo species has an unusual triradicaloid 
electronic structure, resulting from protonation of Glu173, wherein two either parallel or 
unparallel electrons are localized on the Fe-O units and the third one on the protonated 
Glu173 side chain. In spite of being ~9Å away from the active site protonation of Glu173 
resulted in polarization of electron density thereby tuning the reactivity of the peroxo 
intermediate. In such a configuration the barrier for Cmpd 0 and Cmpd I formation is ~2 
kcal/mol and ~12 kcal/mol respectively and the products were formed with high 
exothermicity (Figure 11, B and C). Glu173 is located in the F-helix surrounded by polar 
residues and an easy access to bulk water making its transient protonation likely. This was 
an interesting observation since the peroxo intermediate has been implicated in the C-C 
bond cleavage step catalyzed by CYP51 and other P450 enzymes.48,49,46,50The active site 
structure of CYP51 in such a configuration is depicted in Figure 12. A structural 
comparison of CYP51 with other X-ray crystal structures of other P450s, CYP10151, 
CYP107A152, CYP11953 and CYP5125 revealed an acidic residue that is conserved in F 
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helices of many of these enzymes (Figure 13) indicating that such a proton shuttling 
pathway may exist in other P450s as well.  
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A) 
 
 
 
 
B) 
 
 
 
 
 
 
C) 
 
 
 
 
Figure 11: Geometries and energies along the reaction coordinate for A) His259H+-
Thr260OH mediated transformation of peroxo to Cmpd 0, B) Glu173-(H2O)4-mediated 
transformation of peroxo to Cmpd 0 and C) Glu173-(H2O)4 mediated transformation of 
Cmpd 0 to Cmpd 1. 
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Figure 12: The active site of oxyferrous CYP51. The lanosterol molecule is shown in 
yellow and the (H2O)4 network connecting Glu173 to O2 are shown in a stick 
representation. 
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Figure 13:  Positions of the I-helices, F-helices and structurally conserved acidic residues 
of CYP101 (PDB 1DZ8, magenta), CYP119 (PDB 1IO7, yellow) and CYP107A (PDB 
1Z8O) as compared to Mtb CYP51 (PDB 1X8V, green). 
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     Based on these computational results Glu173, His259 and Thr260 are thought to 
participate in the proton shuttle. These residues stabilize the water channel to shuttle 
protons and orient O2 for protonation.. Because of their pivotal role in CYP51 catalysis it 
was decided to mutate these three key residues in CYP51 active site to alanine and 
characterize the mutants biophysical properties. 
 
2.2   Materials and Methods  
CYP51 expression and purification: Initial attempts to clone the CYP51 wild type 
(CYP51wt) gene in pET 30a gene vector, did not yield much success. The protein 
expressing plasmid, i.e. CYP51wt gene with a C terminal (His)4 tag in pET17b vector was 
a kind gift from Dr. Larissa Podust at UCSF.54 The plasmid was transformed in BL21 
(DE3) cells. The transformants were grown at 37oC in LB broth containing 100mM 
potassium phosphate buffer (pH 7.5), 0.4% v/v glycerol and 100 µg ampicillin. When 
optical density at 600 nm of the culture attained values between 0.5-0.8, protein synthesis 
was induced with the addition of 0.2 mM isopropyl-β-D-thiogalactopyranoside (IPTG) 
(Lab Scientific). 0.5 mM 5-aminolevulinic acid (5-ALA) (Alfa Aesar), a precursor of heme 
biosynthesis, was added. Cells were grown for 20 hrs at 20oC and harvested by 
centrifugation at 5000 rpm for 10 mins. The pelleted cells were gently resuspended in 
buffer A consisting of 500 mM NaCl, 50 mM potassium phosphate (pH 7.5), 0.1mM 
EDTA and 20% (v/v) glycerol. The cell suspension was lysed in a French press at pressure 
exceeding 20,000 psi twice. The lysed cells were separated from cell suspension by 
centrifugation at 20,000 rpm for 20 mins. CYP51 was isolated by using the Ni+2-
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nitrilotriacetic acid (Ni-NTA) affinity column (Qiagen). The column was equilibrated with 
the equilibration buffer consisting of buffer A without 0.1 mM EDTA. The cell lysate was 
loaded onto the Ni-NTA column and washed with a buffer B consisting of 500 mM NaCl, 
50 mM potassium phosphate (pH 7.5), 5 mM imidazole and 20% v/v glycerol, until their 
absorbance maintained a constant value. The protein was eluted by increasing the 
imidazole concentration in buffer B to 50 mM. The eluate was dialyzed overnight in 
50mM potassium phosphate (pH 7.5) and 20% v/v glycerol. Dialyzed sample was further 
purified by size exclusion chromatography using HiLoad™ 26/60 Superdex™75 prep 
grade column (GE healthcare) on a Amersham BioSciences FPLC system. SDS 
polyacrylamide gel electrophoresis (PAGE) analysis was performed at each stage of the 
protein purification on a 7% polyacrylamide gel. The protein molecular weight standard 
was obtained from Biorad. Protein quantitation was done using the Bradford reagent 
(Biorad).55 
CYP51 mutagenesis: A standard protocol was followed for mutagenesis of all the CYP51 
mutants. The CYP51wt plasmid was used as template DNA. The upstream and 
downstream primers (Invitrogen, with changed nucleotides in bold/underlined) for 
Glu173Ala (E173A) are upstream: 5' CTATCACGAGTTGGCGCGCGGCACCGAC 3' 
and downstream: 5' GTCGGTGCCGCGCGCCAACTCGTGATAG 3', His2559Ala 
(H259A) upstream: 5' GTTCGCCGGCCATGCCACCAGCTCGGG 3' and downstream: 5' 
CCCGAGCTGGTGGCATGGCCGGCGAAC 3' and Thr260Ala (T260A) upstream: 5' 
GCCGGCCATCACGCCAGCTCGGGTAC 3' and downstream: 5' 
GTACCCGAGCTGGCGTGATGGCCGGC 3'. Phusion™ High Fidelity PCR Master Mix 
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was used for the Polymerase Chain Reaction (PCR) (New England Biolabs) and nuclease-
free water was used from Promega. A 50 µL reaction was set up using 0.4 ng of template 
DNA, and 0.5 µM primer. Amplification conditions were 98oC for 60 s, 25 cycles of 98oC 
for 10 s, 65-75oC for 25 s and 72oC for 2.00 mins. A final extension was carried out for 
72oC for 10 mins. An annealing temperature gradient was done. Following amplification 
the samples were digested with the enzyme DpnI (New England Biolabs) for one hour. 
DpnI is a restriction endonuclease which digests methylated plasmids, thus retaining only 
those plasmids amplified in vitro. The samples were then concentrated to 10 µL using a 
SpeedVac, 5 µL of which was used to analyze by 1% agarose gel electrophoresis in a 
Biorad gel tank. Agarose gel was prepared by solubilizing 0.5 g of agarose (Biorad) in 50 
ml of Tris-Acetate-EDTA (TAE) buffer. Ethidium bromide (Promega) was added to the 
agarose solution to aid visualization of the amplified bands under UV light. A 1 kb DNA 
ladder (New England Biolabs) was used as reference. Based on amplification results 
(Figure 12) the remaining 5 µL solution was transformed in the NovaBlue GigaSingles™ 
Competent cells (Novagen) using a standard protocol where 5µL of DNA solution was 
added to 50µL of competent cells and incubated on ice for 5 minutes. Cells were then 
subjected to a heat shock at 45oC for 45 seconds and placed back on ice for 2 mins. 250 µL 
of SOC media (Novagen) was added to the cells and they were incubated at 37oC for 1 
hour. Following incubation 50 µL of cells were plated on agar plates containing Ampicillin 
(Fisher) and they were incubated overnight at 37oC. Successful transformants were 
inoculated and grown overnight in 5 mL of LB broth. Plasmids were extracted using the 
QIAprep Spin Miniprep Kit (Qiagen) as per manufacturer’s recommendations. Plasmids 
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were sequenced at the VCU DNA core facility using the universal T7P primers. Those 
showing correct mutations were stored at -20oC. 
Expression and purification of CYP51 mutants: Mutants were purified and expressed 
similarly to the wild type. 
Cloning and expression of Mtb Fdx: A ferredoxin (Fdx) is needed to shuttle electrons 
from a ferredoxin reductase to CYP51 for catalysis to occur. Genomic DNA (gDNA) of 
the Mtb strain H37Rv was obtained from the TB Research Materials and Vaccine Testing 
Contract (NO1 AI-75320) at Colorado State University. Ligation independent cloning 
technique was adapted for cloning of the Mtb Fdx. A pET46-Ek/LIC kit was used from 
Novagen, which consists of all materials required for the cloning. The pET46-Ek/LIC 
vector is an open vector having N terminal (His)6 tag and an enterokinase (Ek) protein 
cleavage site (Figure 14). Primers for Fdx consisted of nucleotides that were 
complementary to the Fdx gene and certain additional nucleotides were added (underlined 
and bold) which are required to generate vector compatible overhangs as per specifications 
mentioned in the accompanying handbook of the kit, upstream-5’ GACGACGACAAG-
ATGGGCTATCGAGAAGCC 3’ and down 5’ GAGGAGAAGCCCGG-
TTACTCTCCCGTTTCTCG 3’. Phusion PCR Master Mix was used as a source of DNA 
polymerase and dNTPs. The PCR reaction was set up using the manufacturer’s 
recommendations. 
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Figure 14:  A map of cloning sites in the pET-46 Ek/LIC vector. (from the Novagen pET-
46 Ek/LIC handbook). 
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The PCR product was analyzed on a 1.3% agarose gel with 100 bp ladder (New England 
Biolabs) as a reference. The amplified band was extracted from the gel using a QIAquick 
Gel Extraction kit (Qiagen) according to manufacturer recommendations. The amplified 
DNA was subjected to a T4 Polymerase treatment to generate vector-compatible 
overhangs. T4 polymerase is an enzyme having dual actions: a 5’- to 3’- polymerase 
activity and a 3’- to 5’- exonuclease activity. In the presence of all nucleotides the 
polymerase balances the exonuclease activity by adding nucleotides in the opposite 
direction. However the system is cleverly unbalanced to generate these overhangs. Because 
only dATP is present along with the polymerase, the exonuclease activity is continued 
until the nucleotide T is reached so that the polymerase can add the nucleotide A. The 
general principal of the working of the ligation independent cloning is depicted in Figure 
15. A 20 µL reaction was initiated by adding the T4 DNA polymerase enzyme to the 
purified PCR product and incubated at 22oC for 30 mins. The enzyme was inactivated by 
heating at 75oC for 20 mins. The polymerase treated PCR product (4 µL) was annealed to 
the pET-46 Ek/LIC vector (1.5 µL), by incubating at 22oC for 5 min. At the end of 5 min, 2 
µL of 25 mM EDTA was added and the reaction was continued for 5 additional minutes. 2 
µL of the annealing reaction was transformed in NovaBlue GigaSingles competent cells 
and plated on ampicillin containing agar plates. Plates were incubated overnight at 37o C. 
From the colonies grown overnight, 13 colonies were selected to screen for the presence of 
insert. They were grown in 5 mL of LB broth and their plasmids were isolated using the 
Qiagen Miniprep Spin kit. A PCR was done using 1 µL of each of the plasmids as template 
DNA, maintaining the concentrations of the other components and reaction conditions as 
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previously described. The PCR products were analyzed on 1.3% agarose gel and those 
showing appropriate amplification sequenced at the VCU DNA core facility. 
     The plasmid bearing correct Fdx sequence was expressed just as CYP51wt with a few 
exceptions. During induction of protein expression, along with 0.2 mM of IPTG, 0.15 mM 
of FeCl3 was added to the media. For protein purification, buffer A contained 5mM of 
imidazole instead of 0.1mM of EDTA. After loading, Ni-NTA column was washed with 
buffer B containing 50 mM of imidazole. To elute the protein imidazole concentration in 
buffer B was increased to 250mM. Proteins were analyzed on a 4-20% gradient PAGE gel 
(Thermo Scientific). 
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Figure 15:  Diagram of the Ek/LIC stategy. (From the Novagen LIC handbook) 
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Cloning and trial expression of Mtb CYP132: A protein BLAST analysis of Mtb 
CYP132 revealed that it was similar to many of the human CYP4V family of P450s, which 
are putative fatty acid oxidizing P450s.56 This was an interesting observation given the 
lipid rich nature of the mycobacterial cell wall. We cloned and tried to express the CYP132 
protein by the LIC strategy. Primers having the sequence upstream 5’ 
GACGACGACAAGATGGCCACCA-CCACCCAGCGGCCCCTGAAG 3’ and 
downstream 5’ GAGGAGAAGCCCGGTTATCGCCTCCTCCCGATGACGTGT-
ACTCCGTG 3’ (Invitrogen) were used to amplify the gene for insertion into pET 46-
Ek/LIC vector. CYP132 cloning methodology was similar to that of Fdx with few 
exceptions in the PCR amplification conditions. At the time of induction of protein 
formation 0.5mM of δ-amino levulinic acid was added to the media. Expression of 
CYP132 proved to be cumbersome because of inability of the protein to express in a 
soluble form. A variety of different conditions were tried for protein expression. Protein 
purification protocol remained similar to that to Fdx. 
Spectral analysis of CYP51wt, CYP51 mutants and Fdx: The oxidized and reduced 
forms of P450 proteins were analyzed in 1.6 mL quartz cuvette on a Shimadzu UV double 
beam spectrophotometer, as per standard protocols.57 The carbonmonoxy (CO) difference 
spectra were determined as per methods described by Omura and Sato.58 Binding assays 
were performed in 1.6 mL quartz cuvette using 25 µM P450 concentration in the dialysis 
buffer. Standard compounds dissolved in ethanol (11.5 mM.for clotrimazole (Sigma) and 
12mM for estradiol) were added to the protein solution in 2 µL aliquots. Same volume of 
ethanol was added to the reference cell and the difference spectra were recorded in the 
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range of 350 nm-550 nm. Binding constants were obtained by plotting a double reciprocal 
plot of  against , using equation , where  is 
slope of the line. For Fdx, just the oxidized and reduced spectra were recorded. 
Reconstitution of FnR/Fdx/CYP51 electron transport: To verify whether the electron 
transport chain was functional in supplying electrons to CYP51 from NADPH via Fdx and 
spinach ferredoxin reductase (FnR), ferrous-CO spectra were obtained. In order to obtain a 
ferrous-CO spectrum, the P450 sample is reduced in both the sample and reference cuvette 
using few grains of sodium hydrosulfite and CO is bubbled in the sample cuvette. Ligation 
of CO to the reduced P450 produces strong absorption maxima at 450 nm. The electron 
transport chain experiment is similar to the ferrous-CO experiment except in this case the 
reduction is performed by FnR and Fdx with NADPH as the electron source (Figure16). 5 
mg CYP51wt, 0.269 mg Fdx, 0.2 Units of FnR were assembled in a 1.6 mL quartz cuvette. 
NADPH was added to both the sample and reference cuvettes and a baseline was recorded. 
Then CO was bubbled in sample cuvette and a difference spectrum was recorded. The 
working of the electron transport chain was investigated in mutants in a similar manner. 
CYP51wt catalytic activity assay: The Mtb CYP51 enzyme is more plant like than 
animal like, hence obtisifoliol which has a 98% turnover rate is a better substrate for the 
catalytic activity than lanosterol, the turnover rate of which is just 1%. On the other hand, 
dihydrolanosterol (DHL) in which the 24,25 double bond is absent, is a better substrate for 
this enzyme with a turnover rate of about 20%.38 Due to commercial unavailability of DHL 
it was made from lanosterol by a one step hydrogenation. (Figure 17) The starting material, 
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Lanosterol (Steraloids, Inc) was assessed for purity by TLC, using a solvent system 
consisting of 90:10 hexane:ethylacetate. It was purified on a silica column using the same 
solvent system and samples were analyzed using 1H-NMR. The reduction reaction was 
carried out in a hydrogenation apparatus using 0.1M of the starting material and 10% PdC 
in ethanol  
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Figure 16:  Electron transport chain in CYP51. Electrons are transferred from NADPH to 
CYP51 via Fdx using FnR. Reduced P450 binds to CO resulting in Soret band at 450 nm 
(inset). 
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Figure 17: One step reduction of lanosterol to dihydrolanosterol. 
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The pressure was set at 35psi and reaction was carried out for 5 hours. After 5 hours the 
reaction was filtered using celite and methanol. The product was dried by evaporating the 
solvent on vacuum. 
      To solubilize DHL, 0.1mM of DHL was dissolved in 1 ml of methanol and added to 16 
mg of Triton WR1339 (Sigma) dissolved in 1 ml of methanol. Methanol was evaporated 
using vacuum and the residue was resuspended in equal volume of water. For the assay 50 
mM potassium phosphate buffer (pH 7.5), 0.5µM of Cyp51wt, 1 µM of Fdx and 0.1 unit of 
Fnr and 0.1 mM of DHL were incubated on ice for 10 mins. Reaction was initiated by 
adding 0.4 mM of NADPH (Sigma) and carried out for 6 hours at 30oC. Product was 
extracted using 5 vol of ethylacetate, which was evaporated to complete dryness in a 
GeneVac centrifugal evaporator. The residue was resuspended in 0.5 ml of methanol and 
injected into Shimadzu LC. The run was set for 40 mins and the solvent sytem was a linear 
gradient of methanol and methanol:water:acetonitrile (45:10:45) over 30 mins and 100% 
methanol for 10 mins.  
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2.3 Results and Discussion: 
Mtb CYP51wt:  The CYP51wt gave an excellent expression (5mg/L culture) of protein in 
the BL21 (DE3) strain of E.coli. A single band at 50 kDa was observed on the SDS-PAGE 
gel, (Figure 18, A). The ferrous-CO spectrum shows a major peak at 450 nm and a smaller 
peak at 420 nm. However, unlike in typical P450s the peak at 450 nm decays to a form of 
the enzyme absorbing at 420 nm.(Figure 18,B-2). This can be attributed to the protonation 
of the cysteine thiolate ligand. The oxidized spectrum of purified CYP51, showed a Soret 
peak at 420nm and the charge transfer bands 573 nm (α) and 541 nm (β). Reduction by 
sodium hydrosulfite (Sigma) resulted in a Soret peak at 423 nm (Figure 18, B-1).  
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A) 
 
 
 
 
 
 
B)  
 
 
 
 
 
 
 
 
Figure 18: Analysis of CYP51wt A) SDS-PAGE gel showing band near 50 kDa. B) UV-
vis spectra of the ferric and ferrous oxidation states of CYP51. C) UV-vis spectra showing 
a collapse of the P450 complex of CYP51 to the P420 complex. 
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    Type I substrate binding in P450s causes a change in the spin state from high spin to low 
spin due to the loss of water as the sixth ligand and the resulting spin shift causes a peak at 
388 nm and a trough at 423 nm in CYP51 (Figure 19, A). The azoles are known inhibitors 
of 14α-demethylase enzymes 59, 60 and these molecules produce a type II spectrum, 
resulting from the direct coordination of the azole to the heme as the sixth ligand. The type 
II spectrum is characterized by a peak at 432 nm and a trough at 411 nm. (Figure 19, B). A 
third type of ligand like n-butanol produce a reverse type I spectra The binding mode of 
type I, II and reverse type I and the resulting difference spectra are summarized in Figure 
19. In both type I and type II ligand spectra, the spectral shift is proportional to the P450-
substrate complex. The binding constants of CYP51wt for estradiol and clotrimazole are 
summarized in Table 2. 
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A) 
 
 
 
B) 
 
 
 
 
C) 
 
 
 
Figure 19: Different type of ligands for P450s A) type I-estradiol B) type II-clotrimazole 
and C) reverse type I-n-butanol. Difference spectra results from the subtraction of the 
water coordinated species from the ligand bound species. 
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A) 
 
 
 
 
 
 
B) 
 
 
 
 
 
 
 
Figure 20: Difference spectra arising from titration of CYP51wt with, (A) 17β-estradiol 
and (B) Clotrimazole. Linear fit to  
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Mtb CYP51 mutants E173A, H259A and T260A: PCR showed good amplification of 
the target plasmid between 4-5kb (Figure 21, A) SDS-PAGE analysis showed a single 
band around the expected 50kDa range (Figure 21, B). Spectral analysis of mutants in 
described in Figure 22 and the peaks observed in the spectra of mutants are summarized as 
follows in Table 3. While H259A and E173A showed comparable spectra to that of the 
wild type, T260A mutant had a few distinct spectral properties. The ferrous species 
showed the presence of an extra peak at around 476 nm and the ferric spectra was quite 
diffused compared to the ferric species of other mutants and the wild type. The P450 
species in the T260A ferrous-CO difference spectra was unstable and it immediately 
collapsed to the P420 species. 
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Table 2: UV-vis spectral characteristics of CYP51 mutants. 
 
Mutant Ferric Ferrous Ferrous-CO, α, β. 
Glu173A 419.2 nm 423 nm 450.8 nm, 574 nm, 541 nm. 
H259A 418.4 nm 425.6 nm 449.2 nm, 574 nm, 542 nm. 
T260A 417.8 nm 425.2 nm 449.6 nm, 476 nm, 575 nm, 541 nm. 
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A) 
 
 
 
 
 
B)  
 
 
 
 
 
Figure 21: Agarose electrophoresis and SDS-PAGE analysis of mutants. A) Agarose gels 
showing PCR amplification of the CYP51 mutants 1) E173A, 2) H259A and 3) T260A 
below 5kb as pointed by the arrow. B) Corresponding SDS-PAGE of the mutants, the 
arrow points from the 50kDa band of the marker to the eluted fraction of the protein.  
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Figure 22: Ferric, Ferrous and Ferrous-CO spectra of CYP51 mutants. A) E173A, 
B) H259A and C) T260A 
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     Binding studies in the mutants using type I and type II ligand yielded values quite 
different from those for wild type, especially for the type I ligand, estradiol. Saturation was 
achieved with low concentrations of imidazole in the titration experiments. The difference 
spectra and linear plots are shown in Figure 23 for estradiol and Figure 24 for clotrimazole. 
Dissociation constants are summarized in Table 2. Binding constants of the mutants for 
estradiol deviated from those for CYP51wt, which can be assumed to be attributed to 
change in active site architecture. Binding constants for the E173A mutant showed 
significant differences in both the type I and II ligand as compared to the CYP51wt. 
Among these mutants, binding spectra of T260A showed the most distinct spectral 
properties. In type I difference spectra it showed a distinct red shift with a peak at 415nm 
and a trough at 380nm. This is quite similar to the difference spectra produced by the 
reverse type I ligand, for example n-butanol and phenacetin.15 This may be attributed to the 
unavailability of a hydrogen bond donor at the active site due to the mutation in the Thr 
residue. 
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Table 3: Dissociation constants for CYP51wt and mutants: 
 
CYP51 Estradiol Clotrimazole 
CYP51wt 151.1 µM 12.8 µM 
E173A 4.9 µM 27.6 µM 
H259A 18.6 µM 11.0 µM 
T260A 34.2 µM 8.5 µM 
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A) 
 
 
 
 
 
B) 
 
 
 
 
 
C) 
 
 
 
 
 
 
Figure 23: Estradiol binding spectra for CYP51 mutants A) E173A, B) H259A and C) 
T260A. The graph on left is the difference binding spectra and on right is the linear plot. 
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Figure 24: Clotrimazole binding spectra for CYP51 mutants A) E173A, B) H259A and C) 
T260A. The graph on left is the difference binding spectra and on right is the linear plot. 
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Mtb Fdx: PCR of the Mtb Fdx gene showed amplification around 200 bp which is 
consistent with the gene length of 207 bp (Figure 25, A-1). Protein expression of Fdx was 
good with a yield of 8 mg/L of culture. SDS PAGE analysis of the protein showed a band 
below the 10 kDa mark (Figure 25, A-2). The spectrum of pure Fdx protein showed a peak 
at 411 nm and absorption shoulders at 450 nm and 550 nm. The reduced protein spectrum 
shows a peak at 311nm (Figure 25, B). All the data was in accordance with published 
literature for similar ferredoxin.61  
Mtb CYP132: PCR of the CYP132 gene showed amplification below 1.5kb mark of the 
DNA ladder consistent with the size of the gene (1386bp) (Figure26, A). Expression of a 
soluble CYP132 protein was unsuccessful. Various temperatures and cells were used to 
express CYP132. However protein invariably ended up in the inclusion bodies as indicated 
by SDS gel analysis comparing with protein ladder at 50kDa. (Figure 26, B). 
Electron transport chain investigation: Electron transport to CYP51wt was investigated 
using ferrous-CO difference spectra experiment. Just as seen for reduction with sodium 
hydrosulfite, at 5 min intervals after reduction a slight peak at 450 nm was seen. Over next 
20 mins the peak at 420 nm increased in amplitude (Figure 27). This is an indication of 
shuttling of electrons from NADPH to CYP51wt, reducing the P450 and allowing it to 
coordinate to CO and proves that Fdx is functional. The spectra for the mutants were 
collected at 3 minute interval and it was noticed that for the T260A and H259A, the rate of 
electron shuttling is an order of magnitude slower than that for E173A. 
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Figure 25:  Analysis of Mtb Fdx. A) (left) PCR amplification of the Mtb Fdx gene 
showing amplification in the 200bp region. (right) SDS-PAGE analysis of Mtb Fdx 
showing a band near 10Da mark of the protein ladder. B) (left) Oxidized and (right) 
reduced spectra of Mtb Fdx. 
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A) 
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Figure 26:  Agarose gel electrophoresis and SDS-PAGE analysis of Mtb CYP132 A) PCR 
amplification of CYP132. B) SDS PAGE analysis of CYP132, 1) Protein expressed at in 
BL21 cells at 25oC. 2) Protein expressed in Origami DE-3 cells at 20oC. IPTG 
concentration was maintained low (0.1-0.2mM) in both the conditions. 
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1 2 
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CYP51wt catalytic activity assay:  In the one step hydrogenation step to make DHL the 
purified starting material had Rf value of 0.48, its 1H-NMR spectrum is shown in Figure 28 
A. Completion of the reaction was checked on UV. Since the end product was UV-
invisible it was analyzed by 1H-NMR (Figure 28 B). Repeated attempts to perform 
catalytic activity didn’t yield much success mainly due to failed attempts to solubilize 
insolubility of DHL in water. In all experiments DHL couldn’t be dissolved in the solution, 
which may have prevented it from being accessible to the enzyme. 
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Figure 27:  Difference spectra supporting electron transport from NADPH to CYP51, 
gradual increase in P420 peak indicating reduced P450 coordinating to CO, A)CYP51wt, 
B)T260A, C) H259A and D) E173A. 
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Figure 28: 1H-NMR profiles of A) lanosterol and B) DHL. 
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CHAPTER 3: Resonanace Raman spectroscopy of CYP51wt and T260A 
 
 
3.1   Introduction:  
Raman effect is an inelastic scattering phenomenon of light.62 When a light wave, 
considered as an oscillating dipole, interacts with a molecule some part of the light is 
absorbed by it and causes polarization. This induces an instantaneous dipole moment in the 
molecule. The induced dipole µind, depends on the applied field E and ease with which the 
electrons in a molecule are distorted, 
µind = αE 
where α is the polarizability of the molecule.63 When a molecule is excited from ground 
vibrational level and returns to the same state the frequency of scattered light is identical to 
incident frequency giving rise to Rayleigh scattering. However, if the excited molecule 
returns back to a higher (Stokes) or a lower vibrational state (Anti- Stokes) than what it 
started in, it results in Raman scattering (Figure 29). 
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Figure 29: Diagrammatic description of Raman scattering. 
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When an intense radiation is used to excite a chromophore, light absorbed in the molecule 
causes strong fluorescence or photodecomposition of the molecule. This hinders Raman 
detection. However if the sample is excited using a laser at a frequency closer to that of the 
chromophore, it will give more efficient scattering and more information can be obtained 
about the electronic and vibrational properties of the sample. This forms the underlying 
basis of resonance Raman technique. To obtain resonance Raman spectra a laser beam 
having excitation frequency closer to that of the electronic transition of the molecule under 
study is chosen. The intensity of Raman scattering is defined by 
I = Klα2ω4 
where, K consists of constants such as speed of light, l is the laser power, ω is the 
frequency of incident radiation and α is the polarizability of electrons in the molecule.63 
The resonant condition is met when the energy of exciting light matches the energy 
difference between the lowest vibrational state of the ground electronic state and the 
resonant vibronic state. Under this condition polarizability increases giving intense Raman 
scattering. Resonance Raman spectroscopy differs from Raman spectroscopy in the nature 
of interactions of vibronic states. Under resonating conditions most of the interaction is 
with one vibronic state, so the scattering is wholly dependent on properties of that state. 
     In recent years resonance Raman spectroscopy has become a useful tool technique to 
study heme containing enzymes.64 The resonance Raman scattering of heme enzymes is 
attributed to an interaction with π-π* transitions from the porphyrin ring of the heme 
group. Resulting vibrations from resonance Raman scattering can be assigned to certain 
structural properties. Vibrations shown in Figure 30 are markers for the oxidation and spin 
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Figure 30: Typical vibrations in heme and their corresponding markers in resonance 
Raman spectra. 63 
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 state of the Fe ion in prophyrin.63 The υ4 band at ~1373nm is the strongest. It results from 
the oxidation state of the Fe and major contribution to the υ4 band is symmetric inward or 
outward in phase vibrations of the N atoms pyrrole rings coordinated to the central Fe 
atom. This movement alters the size of the cavity in which the Fe ion sits. The size of the 
Fe changes with oxidation state making υ4 band a marker of oxidation state of the central 
ion. The υ3 and υ10 are markers for the spin state of the Fe ion. Both these vibrations cause 
significant movement of the inner atoms of the porphyrin. Other vibrations result from the 
in-plane and out-of-plane movements of porphyrin ring. Since P450s have intense Soret 
absorption at 410 – 450nm, excitation of frequency close to the Soret absorption band 
produces Raman scattering enhancing the contributions from totally symmetric A1g modes 
of vibrations and enabling elucidation of the heme environment. 
     Resonance Raman spectra were collected for CYP51 and T260A mutant of CYP51 to 
probe the impact of mutation on the heme environment. 
3.2:  Materials and Methods:  
Resonance Raman spectra was obtained using 5 mw or less of 406.7 nm radiation of the 
sample,~0.1 mM of CYP51 and T260A The laser used was a Coherent Sabre DBW 
krypton ion laser and the spectra was acquired using a Princeton Instruments N2(l) cooled 
1340 x 400 CCD detector. The spectrometer was a Spex model 1870 0.5 m spectrometer 
fitted with a 1200 or 1800 line/mm holographic grating (Jobin-Yvon). Sample exposure 
times were 2 to 4 minutes. The samples were contained in a quartz Raman spinning cell 
that was stoppered with a septum. The spinning cell apparatus was from Spex. KCN and 
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NO were used to record spectra with diatomic ligands. Sodium hydrosulfite was used to 
reduce samples. A general setup of the Raman spectrometer is shown in Figure 31. 
 
3.3: Results and Discussion: 
The resonance Raman spectra for the CYP51wt and T260A mutants were recorded in the 
ferric, ferrous, NO-ligated and CN- ligated forms. The wild type and the mutant forms have 
been compared and shown in Figure 32A-ferric CYP51wt and ferric CYP51T260A, 32B-
ferrous CYP51wt and ferrous CYP51T260A, Figure 33A- ferric CYP51wt_CN and ferric 
CYP51T260A_CN, 33B-ferrous CYP51wt_CN and ferrous CYP51T260A_CN and Figure 
34A- ferric CYP51wt_NO and ferric CYP51T260A_NO, 34B-ferrous CYP51wt_NO and 
ferrous CYP51T260A_NO. The υ3 band, which is a marker of the spin state, of ferric T260 
mutant shows a distinct split as compared to the υ3 of ferric wild type enzyme indicating 
the presence of an admixture of two spin states. This suggests that the Thr260 may be 
involved in hydrogen bonding to the water molecule in order to hold it in place over the 
heme enzyme, thus helping heme to maintain its low spin hexa coordinate form. 
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Figure 31:  Diagrammatic representation of resonance Raman experimental setup. 
(courtesy Dr. James Terner) 
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Figure 32: Resonance Raman spectra of A) ferric CYP51wt and T260A, B) ferrous 
CYP51wt and T260A. 
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A) 
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Figure 33: Resonance Raman spectra of A) ferric-CN CYP51wt and T260A, B) ferrous-
CN CYP51wt and T260A. 
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Figure 34: Resonance Raman spectra of A) ferric-NO CYP51wt and T260A, B) ferrous-
NO CYP51wt and T260A. 
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Conclusions 
 
 
1) CYP51wt and its mutants E173A, H259A and T260A which were made using site 
directed mutagenesis were successfully expressed. Their analysis by UV-vis spectroscopy 
gave information about their binding constants for the type I and type II ligands. It also 
indicated the unusual spectral characteristics of the T260A mutant. 
2) Fdx, a conduit protein which is required to shuttle electrons for CYP51 catalysis was 
successfully cloned into pET46 Ek/LIC vector and expressed. Its spectral characteristics 
were similar as in published literature for other similar ferrdoxins. Fdx was found to 
support the electron transport chain to shuttle electrons from NADPH to CYP51wt as 
indicated by the ferrous-CO difference spectra. 
3) Resonance Raman experiments revealed an interesting admixture of spin states in ferric 
T260A. This can be attributed to the loss of hydrogen bond between Thr260 and H2O, thus 
causing the enzyme to exist in penta coordinate high spin form. 
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